Literature DB >> 19886145

Groin herniorrhaphy in patients with cirrhosis and after liver transplantation.

Elise H Lawson1, Elizabeth Benjamin, Ronald W Busuttil, Jonathan R Hiatt.   

Abstract

We report on 43 groin herniorrhaphy operations, 18 in 18 patients with documented cirrhosis and 25 in 24 patients after liver transplantation (LT), over a 10-year period at UCLA. Average follow up was 33 months. Most patients were males (84%) with reducible inguinal hernias (70%). Child's class of cirrhotic patients was B in 66 per cent and A and C in 17 per cent each; 7 patients (39%) went on to LT. Compared with post-LT patients, patients with cirrhosis had significantly lower platelets and significantly higher bilirubin, international normalized ratio, and Model for Endstage Liver Disease scores. Mesh was used in 33 per cent of the cirrhotic group and 48 per cent of the LT group. There were four minor wound complications but no deaths, major complications, infections, or ascitic leaks in either group. Two hernias recurred in the cirrhosis group (11%) and none after LT. We conclude that with proper patient selection, groin herniorrhaphy with or without mesh is a safe and durable procedure in patients with cirrhosis and after LT. This is the first large series of groin herniorrhaphy after LT.

Entities:  

Mesh:

Year:  2009        PMID: 19886145

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  2 in total

1.  Inguinal hernia repair in patients with cirrhosis is not associated with increased risk of complications and recurrence.

Authors:  Heung-Kwon Oh; Hansuk Kim; Seungbum Ryoo; Eun Kyung Choe; Kyu Joo Park
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

2.  Laparoscopic totally extraperitoneal (TEP) inguinal hernia repair in patients with liver cirrhosis accompanied by ascites.

Authors:  Haiyang Wang; Jian Fu; Xiaotong Qi; Jianming Sun; Yikuan Chen
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.